CEO of AMP and Corporate Director of Research for U.S. Urology Partners, Christopher Pieczonka, M.D., serves as global principal investigator for a clinical study delivering promising interim results for patients with non-muscle invasive bladder cancer (NMIBC).
“The interim results from this randomized study are encouraging and suggest that Anktiva plus BCG may improve the durability of response in patients with BCG-naïve NMIBC,” said global principal investigator Christopher M. Pieczonka, MD, Corporate Director of Clinical Research at U.S. Urology Partners, in the news release. “Given the historical limitations of BCG alone, continued evaluation of this combination has the potential to inform future treatment strategies and potentially change the current standard-of-care recommendations for NMIBC. Importantly, no new or worsening safety signals have been observed to date, which is encouraging when considered alongside prior studies evaluating BCG in combination with checkpoint inhibitors in this disease setting.”
